Robert H. Vonderheide
Affiliations: | Cell and Molecular Biology | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Cell Biology, Immunology, OncologyGoogle:
"Robert Vonderheide"Parents
Sign in to add mentor| Simon V. Hunt | grad student | 1987-1990 | Sir William Dunn School of Pathology University of Oxford (Neurotree) | |
| (Since 2017, Director Abramson Cancer Center, John H. Glick Abramson Cancer Center Professor, UPenn.) | ||||
Children
Sign in to add trainee| Erica L. Carpenter | grad student | 2009 | Penn |
| Lauren J. Bayne | grad student | 2012 | Penn |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kim IK, Diamond MS, Yuan S, et al. (2024) Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. Nature Communications. 15: 1532 |
| Blise KE, Sivagnanam S, Betts CB, et al. (2023) Machine learning links T cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer. Biorxiv : the Preprint Server For Biology |
| Cheng NC, Vonderheide RH. (2023) Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends in Cancer |
| Kim IK, Diamond M, Yuan S, et al. (2023) Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy. Research Square |
| Kim R, Taylor D, Vonderheide RH, et al. (2023) Ferroptosis of immune cells in the tumor microenvironment. Trends in Pharmacological Sciences |
| Schratz KE, Flasch DA, Atik CC, et al. (2023) T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers. Cancer Cell. 41: 807-817.e6 |
| Kemp SB, Cheng N, Markosyan N, et al. (2022) Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discovery |
| Padrón LJ, Maurer DM, O'Hara MH, et al. (2022) Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine |
| Bear AS, Blanchard T, Cesare J, et al. (2021) Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications. 12: 4365 |
| Diamond MS, Lin JH, Vonderheide RH. (2021) Site-dependent immune escape of highly antigenic tumors without immunoediting. Cancer Immunology Research |